Pharsight

Pexeva patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598271 SEBELA IRELAND LTD Crystalline paroxetine methane sulfonate
May, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5874447 SEBELA IRELAND LTD 4-Phenylpiperidine compounds for treating depression
Jun, 2017

(6 years ago)

Pexeva is owned by Sebela Ireland Ltd.

Pexeva contains Paroxetine Mesylate.

Pexeva has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Pexeva are:

  • US5874447

Pexeva was authorised for market use on 03 July, 2003.

Pexeva is available in tablet;oral dosage forms.

Pexeva can be used as depression.

The generics of Pexeva are possible to be released after 04 May, 2025.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using PAROXETINE MESYLATE ingredient

Market Authorisation Date: 03 July, 2003

Treatment: Depression

Dosage: TABLET;ORAL

More Information on Dosage

PEXEVA family patents

Family Patents